Programming - Hypertension Scientific Sessions 2021

2021 Programming Schedule

3 Days of programming beginning 10:00 a.m. Central Time Monday

Monday, September 27 10:00 a.m. Central Time

We are excited to announce the conference will open with the recipient of the 2019 Nobel Prize in Physiology or Medicine:

Gregg L. Semenza, MD, PhD


Gregg L. Semenza, MD, PhD, Director, Vascular Program, Institute for Cell Engineering

Professor of Genetic Medicine, Johns Hopkins University, 2019 Nobel Prize in Physiology or Medicine

Presenting: Hypoxia-Inducible Factors in Physiology and Medicine.

Downloads

Schedules

Choose from the following links to download a schedule in a detailed or broad format.

Hypertension Conference Program Committee Chairs

 

R. Ariel Gomez, MD, FAHA

Chair
R. Ariel Gomez, MD, FAHA
University of Virginia

 

Alexander Staruschenko, PhD, FAHA

Vice-Chair
Alexander Staruschenko, PhD, FAHA
University of South Florida

 

Daichi Shimbo, MD

Clinical Chair
Daichi Shimbo, MD
Columbia University, Irving Medical Center

 

 

Co-Chair, Clinical Programming Subcommittee
Aisha Langford, PhD, MPH
NYU Langone Health

 

Co-Chair, Clinical Programming Subcommittee
J. Brian Byrd, MD, MS, FACC, FAHA
University of Michigan Health

Hypertension Conference Program Committee Immediate Past Chairs

 

Curt D. Sigmund, PhD, FAHA

Immediate Past Chair
Curt D. Sigmund, PhD, FAHA
Medical College of Wisconsin

 

Vivek Bhalla, MD, FAHA

Immediate Past Vice-Chair
Vivek Bhalla, MD, FAHA
Stanford University

Hypertension Conference Program Committee Members

 

 

Christopher Banek, PhD
Jan Basile, MD
Michael Bloch, MD
Angela Brown, MD
Debbie Cohen, MD
Denise Cornelius, PhD
Leslie Davis, PhD
William Elliott, MD, PhD
David Ellison, MD
Yumei Feng Earley, MD, PhD
Karen Griffin, MD
Justin Grobe, PhD
Robert Hoover, MD

 

Kenneth Jamerson, MD
Eric Lazartigues, PhD
Mitra Nadim, MD
Aldo Peixoto, MD
Gary Schwartz, MD
Zhongjie Sun, MD, PhD, MS
Sandra Taler, MD
Elaine Urbina, MD, MS
Richard Wainford, PhD
Stephanie Watts, PhD
R. Clinton Webb, PhD
Camilla F. Wenceslau, PhD
Brandi Wynne, PhD, MS

What's new for 2021

We know this has been an exceptionally challenging year in so many ways. We want to recognize all the research and clinical work that has been performed during this difficult time. Therefore, attendees can expect that the program will be dedicated to important and innovative clinical topics in hypertension as well as research performed by our members and attendees. The latter will primarily include abstract presentations.

Expectations of the program

  • COH and KCVD Awards Program
  • Keynote Lecture 
  • Clinical science and primary care sessions 
  • Symposia on hot topics 
  • Basic and translational science weighted toward presentations derived from submitted abstracts

About This Meeting

Hypertension 2021 Scientific Sessions, focusing on recent advances in basic and clinical research on hypertension, is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.

Target Audience

The conference is designed to benefit research scientists, clinicians, and other healthcare professionals in the fields of hypertension research, cardiology, nephrology, endocrinology and related disciplines.

Learning Objectives

  1. Discuss changes to the AHA/ACC guidelines for the management of hypertension and their clinical implications.
  2. Describe opportunities to improve blood pressure measurement in the clinical setting to provide more accurate results.
  3. Identify immune and inflammatory mechanisms that contribute to the development of hypertension and hypertension-related end-organ damage and discuss the research and clinical implications.
  4. Educate participants about medical approaches for the management of comorbid obesity in patients with hypertension.
  5. Describe new and emerging strategies for treating resistant hypertension.
  6. Describe participants on the impact of value-based reimbursement on hypertension management and identify opportunities to improve its management.